지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 857 - 870 (14page)
이용수
초록· 키워드
오류제보하기
Warfarin is a frequently prescribed anticoagulant in rehabilitation patients. Adverse drug reactions of warfarin were reported as bleeding and cutaneous microvascular thrombosis. Major bleeding, such as intracranial hemorrhage and psoas hematoma, in patients receiving anticoagulation therapy is a rare condition, but sometimes very serious complication that can even be fatal. Patient-specific factors (eg, age, body size, race, concurrent diseases, and medications) explain some of the individual variability in warfarin dose, but genetic factors, which influence warfarin response, explain a significantly higher proportion of the variability in the dose. There are two identified genes that are responsible for the main proportion of the genetic effect: CYP2C9, which codes for the enzyme cytochrome P450 2C9 that metabolizes S-warfarin, and VKORC1, which codes for warfarin’s target, vitamin K epoxide reductase. We report a case of intolerance to warfarin dosing, due to impaired drug metabolism in a patient with CYP2C9*1/*3 and VKORC 1173TT. Fortunately, there are no severe complications.
목차
등록된 정보가 없습니다.
참고문헌 (10)
참고문헌 신청
Aithal GP / 1999 / Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications / Lancet 353 : 717 ~ 719
Cho HJ / 2007 / Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients / Pharmacogenomics 8 : 329 ~ 337
Cruickshank J / 2001 / Warfarin toxicity in the emergency department : recommendations for management / Emerg Med 13 : 91 ~ 97
Higashi MK / 2002 / Association between CYP2C9 genetic variants and anticoagulation- related outcomes during warfarin therapy / JAMA 287 : 1690 ~ 1698
Hirsh J / 2001 / Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range / Chest 119 (1) : 8 ~ 21
Cho HJ / 2007 / Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients / Pharmacogenomics 8 : 329 ~ 337
Cruickshank J / 2001 / Warfarin toxicity in the emergency department : recommendations for management / Emerg Med 13 : 91 ~ 97
Higashi MK / 2002 / Association between CYP2C9 genetic variants and anticoagulation- related outcomes during warfarin therapy / JAMA 287 : 1690 ~ 1698
Hirsh J / 2001 / Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range / Chest 119 (1) : 8 ~ 21
이 논문의 저자 정보
최근 본 자료
댓글(0)
0